TrialAntimicrobial agents and chemotherapy2012

No effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in healthy subjects.

Manoli Vourvahis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.